These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22337983)

  • 21. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
    J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests.
    Gage JC; Sadorra M; Lamere BJ; Kail R; Aldrich C; Kinney W; Fetterman B; Lorey T; Schiffman M; Castle PE;
    J Clin Microbiol; 2012 Jan; 50(1):61-5. PubMed ID: 22075592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
    Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
    Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.
    Bhatia R; Serrano I; Wennington H; Graham C; Cubie H; Boland E; Fu G; Cuschieri K
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
    Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping.
    Lee HP; Cho W; Bae JM; Shin JY; Shin SK; Hwang SY; Min KT; Kim SN; Lee SJ; Kim SO; Yoo WD; Hong SP
    J Clin Virol; 2013 Jun; 57(2):130-5. PubMed ID: 23410688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples.
    Cañadas MP; Cirigliano V; Darwich L; Sirera G; Coll J; Clotet B; Videla S
    J Virol Methods; 2012 Jul; 183(1):14-8. PubMed ID: 22449759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay.
    Halfon P; Benmoura D; Agostini A; Khiri H; Martineau A; Penaranda G; Blanc B
    J Clin Virol; 2010 Feb; 47(2):177-81. PubMed ID: 20022804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus detection and genotyping, by HC2, full-spectrum HPV and molecular beacon real-time HPV assay in an Irish colposcopy clinic.
    Keegan H; Pilkington L; McInerney J; Jeney C; Benczik M; Cleary S; von Bunau G; Turner M; D'Arcy T; O' Toole S; Pal-Szenthe B; Kaltenecker B; Mózes J; Kovács A; Solt A; Bolger N; O'Leary J; Martin C
    J Virol Methods; 2014 Jun; 201():93-100. PubMed ID: 24583109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.
    Barzon L; Militello V; Pagni S; Palù G
    J Clin Virol; 2012 Nov; 55(3):256-61. PubMed ID: 22877561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes.
    Didelot MN; Boulle N; Damay A; Costes V; Segondy M
    J Med Virol; 2011 Aug; 83(8):1377-82. PubMed ID: 21678441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.
    Kwon MJ; Roh KH; Park H; Woo HY
    J Clin Virol; 2014 Apr; 59(4):246-9. PubMed ID: 24568964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.